Concepedia

Author

Yeonghak Bang

University of Ulsan

Also Known As

YEONGHAK BANG, Yeonghak Bang

16

Publications

265

Citations

8

H-Index

9

Concepts

All Affiliations

University of UlsanUlsan CollegeAsan Medical CenterVita-Salute San Raffaele UniversityIstituto Oncologico Veneto
YB

About

Yeonghak Bang is an author at University of Ulsan specializing in hepatology, pharmacotherapy, and cancer therapeutics.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

1

1

18

2

Hepatology

1

1

18

3

Pathology

1

1

18

4

Pharmacology

1

1

18

5

Cancer Therapeutics

1

1

18

Yeonghak Bang

×

8

Publications

259

Citations

8

H-Index

YearCitations

Lenvatinib versus sorafenib in first‐line treatment of unresectable hepatocellular carcinoma: An inverse probability of treatment weighting analysis

Andrea Casadei‐Gardini, Mario Scartozzi, Toshifumi Tada,

Liver International

2021

60

Real-World Efficacy and Safety of Lenvatinib in Korean Patients with Advanced Hepatocellular Carcinoma: A Multicenter Retrospective Analysis

Jaekyung Cheon, Hong Jae Chon, Yeonghak Bang,

Liver Cancer

2020

53

Regorafenib in patients with advanced Child‐Pugh B hepatocellular carcinoma: A multicentre retrospective study

Hyung‐Don Kim, Yeonghak Bang, Myung Ah Lee,

Liver International

2020

46

Regorafenib in previously treated advanced hepatocellular carcinoma: Impact of prior immunotherapy and adverse events

Changhoon Yoo, Seonggyu Byeon, Yeonghak Bang,

Liver International

2020

44

Regorafenib versus cabozantinb as second-line treatment after sorafenib for unresectable hepatocellular carcinoma: matching-adjusted indirect comparison analysis

Andrea Casadei‐Gardini, Lorenza Rimassa, Margherita Rimini,

Journal of Cancer Research and Clinical Oncology

2021

18

Rivaroxaban <i>Versus</i> Low-molecular-weight Heparin for Venous Thromboembolism in Advanced Upper Gastrointestinal Tract and Hepatopancreatobiliary Cancer

Jwa Hoon Kim, Seyoung Seo, Kyu‐pyo Kim,

In Vivo

2020

15

Role of the prognostic nutritional index in predicting survival in advanced hepatocellular carcinoma treated with regorafenib

Margherita Rimini, Changoon Yoo, Sara Lonardi,

Hepatology Research

2021

13

Sequential Treatment of Sorafenib–Regorafenib Versus Sorafenib–Physician’s Choice: A Propensity Score-Matched Analysis

Yeonghak Bang, Changhoon Yoo, Sara Lonardi,

Targeted Oncology

2021

10

Page 1